Peptide analogs that inhibit IgE-Fc epsilon RI alpha interactions ameliorate the development of lethal graft-versus-host disease

Autor: Korngold R, Ba, Jameson, Jm, Mcdonnell, Leighton C, Bj, Sutton, Hannah Gould, Gf, Murphy

Publikováno v: Europe PubMed Central

Significant increases in serum levels of IgE have often been observed in allogeneic bone marrow transplantation patients and have generally been thought to be diagnostic of graft-versus-host disease (GVHD), rather than an agent involved in the pathog

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid_dedup__::eff200076ef785244f523122cef6e8bf
https://pubmed.ncbi.nlm.nih.gov/9360780

An attractor state zone precedes neural crest fate in melanoma initiation.

Autor: McConnell AM; Stem Cell Program and Division of Hematology/Oncology, Children's Hospital Boston, Howard Hughes Medical Institute, Boston, MA 02115, USA.; Harvard Stem Cell Institute, Boston, MA 02115, USA.; Harvard Medical School, Boston, MA 02115, USA., Chassé MH; Stem Cell Program and Division of Hematology/Oncology, Children's Hospital Boston, Howard Hughes Medical Institute, Boston, MA 02115, USA.; Harvard Stem Cell Institute, Boston, MA 02115, USA.; Harvard Medical School, Boston, MA 02115, USA., Noonan HR; Stem Cell Program and Division of Hematology/Oncology, Children's Hospital Boston, Howard Hughes Medical Institute, Boston, MA 02115, USA.; Harvard Stem Cell Institute, Boston, MA 02115, USA.; Harvard Medical School, Boston, MA 02115, USA.; Biological and Biomedical Sciences Program, Harvard Medical School, Boston, Massachusetts 02115, USA., Mito JK; Stem Cell Program and Division of Hematology/Oncology, Children's Hospital Boston, Howard Hughes Medical Institute, Boston, MA 02115, USA.; Harvard Stem Cell Institute, Boston, MA 02115, USA.; Harvard Medical School, Boston, MA 02115, USA.; Department of Pathology, Brigham and Women's Hospital, Boston, MA 02215, USA., Barbano J; Stem Cell Program and Division of Hematology/Oncology, Children's Hospital Boston, Howard Hughes Medical Institute, Boston, MA 02115, USA., Weiskopf E; Stem Cell Program and Division of Hematology/Oncology, Children's Hospital Boston, Howard Hughes Medical Institute, Boston, MA 02115, USA., Gosselink IF; Stem Cell Program and Division of Hematology/Oncology, Children's Hospital Boston, Howard Hughes Medical Institute, Boston, MA 02115, USA., Prasad M; Stem Cell Program and Division of Hematology/Oncology, Children's Hospital Boston, Howard Hughes Medical Institute, Boston, MA 02115, USA.; Harvard Stem Cell Institute, Boston, MA 02115, USA.; Harvard Medical School, Boston, MA 02115, USA., Yang S; Stem Cell Program and Division of Hematology/Oncology, Children's Hospital Boston, Howard Hughes Medical Institute, Boston, MA 02115, USA.; Harvard Stem Cell Institute, Boston, MA 02115, USA.; Harvard Medical School, Boston, MA 02115, USA., Abarzua P; Program in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Boston, MA 02215, USA., Lian CG; Program in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Boston, MA 02215, USA., Murphy GF; Program in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Boston, MA 02215, USA., Trapnell C; Department of Genome Sciences, University of Washington, Seattle, WA, 98195, USA., Zon LI; Stem Cell Program and Division of Hematology/Oncology, Children's Hospital Boston, Howard Hughes Medical Institute, Boston, MA 02115, USA.; Harvard Stem Cell Institute, Boston, MA 02115, USA.; Harvard Medical School, Boston, MA 02115, USA.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2024 Oct 25. Date of Electronic Publication: 2024 Oct 25.

Craters on the melanoma surface facilitate tumor-immune interactions and demonstrate pathologic response to checkpoint blockade in humans.

Autor: Ludin A; Harvard Stem Cell and Regenerative Biology Department, Harvard University; Boston, MA, USA.; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute; Boston, MA, USA.; These authors contributed equally., Stirtz GL; Harvard Stem Cell and Regenerative Biology Department, Harvard University; Boston, MA, USA.; These authors contributed equally., Tal A; Harvard Stem Cell and Regenerative Biology Department, Harvard University; Boston, MA, USA., Nirmal AJ; Department of Dermatology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA.; Ludwig Center at Harvard; Boston, MA, USA.; Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA, 02115, USA.; Department of Systems Biology, Harvard Medical School; Boston, MA, USA., Besson N; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Jones SM; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Pfaff KL; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Manos M; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Liu S; Biophysics Program, Harvard University, Boston, MA 02115, USA.; Harvard-MIT Division of Health Sciences and Technology, Massachusetts Institute of Technology, Cambridge, MA 02139, USA.; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA.; Ragon Institute of MGH, MIT and Harvard, Cambridge, MA 02139, USA., Barrera I; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Gong Q; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Rodrigues CP; Harvard Stem Cell and Regenerative Biology Department, Harvard University; Boston, MA, USA.; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute; Boston, MA, USA., Sahu A; Dermatology Service, Memorial Sloan Kettering Cancer Center; New York, NY, USA.|., Jerison E; Department of Physics, University of Chicago, Chicago, IL 60637, USA, Institute for Biophysical Dynamics, and James Franck Institute., Alessi JV; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Ricciuti B; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Richardson DS; Harvard Center for Biological Imaging, Department of Molecular and Cellular Biology, Harvard University; Cambridge, MA, USA., Weiss JD; Harvard Stem Cell and Regenerative Biology Department, Harvard University; Boston, MA, USA., Moreau HM; Harvard Stem Cell and Regenerative Biology Department, Harvard University; Boston, MA, USA., Stanhope ME; Harvard Stem Cell and Regenerative Biology Department, Harvard University; Boston, MA, USA., Afeyan AB; Harvard Stem Cell and Regenerative Biology Department, Harvard University; Boston, MA, USA., Sefton J; Harvard Stem Cell and Regenerative Biology Department, Harvard University; Boston, MA, USA., McCall WD; Harvard Stem Cell and Regenerative Biology Department, Harvard University; Boston, MA, USA., Formato E; Harvard Stem Cell and Regenerative Biology Department, Harvard University; Boston, MA, USA.; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute; Boston, MA, USA., Yang S; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute; Boston, MA, USA., Zhou Y; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute; Boston, MA, USA., van Konijnenburg DPH; Division of Immunology, Boston Children's Hospital and Department of Pediatrics, Harvard Medical School, Boston, MA, USA., Cole HL; Harvard Stem Cell and Regenerative Biology Department, Harvard University; Boston, MA, USA., Cordova M; Dermatology Service, Memorial Sloan Kettering Cancer Center; New York, NY, USA.|., Deng L; Dermatology Service, Memorial Sloan Kettering Cancer Center; New York, NY, USA.|., Rajadhyaksha M; Dermatology Service, Memorial Sloan Kettering Cancer Center; New York, NY, USA.|., Quake SR; Department of Bioengineering and Applied sciences, Stanford University, Stanford, CA, USA.; Chan Zuckerberg Biohub, San Francisco, CA, USA., Awad MM; Lowe Center for Thoracic Oncology, Dana-Farber Cancer Institute, Boston, MA, USA., Chen F; Harvard Stem Cell and Regenerative Biology Department, Harvard University; Boston, MA, USA.; Broad Institute of MIT and Harvard, Cambridge, MA 02142, USA., Sorger PK; Ludwig Center at Harvard; Boston, MA, USA.; Laboratory of Systems Pharmacology, Department of Systems Biology, Harvard Medical School, Boston, MA, 02115, USA.; Department of Systems Biology, Harvard Medical School; Boston, MA, USA., Hodi FS; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of medical Oncology, Dana-Farber Cancer Institute, Boston, MA 02215.; Parker Institute for Cancer Immunotherapy., Rodig SJ; Center for Immuno-Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA., Murphy GF; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA 02115, USA., Zon LI; Harvard Stem Cell and Regenerative Biology Department, Harvard University; Boston, MA, USA.; Stem Cell Program and Division of Hematology/Oncology, Boston Children's Hospital and Dana-Farber Cancer Institute; Boston, MA, USA.; Howard Hughes Medical Institute, Harvard medical school; Boston MA, USA.

Publikováno v: BioRxiv : the preprint server for biology [bioRxiv] 2024 Sep 19. Date of Electronic Publication: 2024 Sep 19.

Immune Profiling of Dermatologic Adverse Events from Checkpoint Blockade Using Tissue Cyclic Immunofluorescence: A Pilot Study.

Autor: Maliga Z; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts, USA., Kim DY; Harvard-MIT Health Sciences and Technology Program, Harvard Medical School, Boston, Massachusetts, USA., Bui AN; Department of Dermatology, The Center for Cutaneous Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts, USA., Lin JR; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts, USA., Dewan AK; Department of Dermatology, Vanderbilt University Medical Center, Nashville, Tennessee, USA., Jadeja S; Program in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Murphy GF; Program in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Nirmal AJ; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts, USA., Lian CG; Program in Dermatopathology, Department of Pathology, Brigham and Women's Hospital, Boston, Massachusetts, USA., Sorger PK; Laboratory of Systems Pharmacology, Harvard Medical School, Boston, Massachusetts, USA., LeBoeuf NR; Department of Dermatology, The Center for Cutaneous Oncology, Dana-Farber Cancer Institute and Brigham and Women's Hospital, Boston, Massachusetts, USA. Electronic address: nleboeuf@partners.org.

Publikováno v: The Journal of investigative dermatology [J Invest Dermatol] 2024 Aug; Vol. 144 (8), pp. 1887-1890.e5. Date of Electronic Publication: 2024 Feb 14.

Lymphadenopathy and lymph node rejection following facial vascularized composite allotransplantation.

Autor: Kauke-Navarro M; Department of Surgery, Division of Plastic and Reconstructive Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, USA., Sadigh S; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Lee CAA; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Panayi AC; Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Knoedler L; Department of Surgery, Division of Plastic and Reconstructive Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, USA., Knoedler S; Department of Surgery, Division of Plastic and Reconstructive Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, USA; Department of Surgery, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Stoegner V; Department of Surgery, Division of Plastic and Reconstructive Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, USA; Department of Plastic, Aesthetic, Hand and Reconstructive Surgery, Burn Center, Hannover Medical School, Hannover, Germany., Huelsboemer L; Department of Surgery, Division of Plastic and Reconstructive Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, USA., Jamil A; Department of Medicine, Transplantation Research Center, Renal Division, Brigham and Women's Hospital and Children's Hospital, 221 Longwood Ave, Boston, MA, USA., Ko C; Department of Pathology, Yale School of Medicine, New Haven, CT, USA., Lian CG; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Murphy GF; Department of Pathology, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA., Pomahac B; Department of Surgery, Division of Plastic and Reconstructive Surgery, Yale New Haven Hospital, Yale School of Medicine, New Haven, CT, USA. Electronic address: bohdan.pomahac@yale.edu.

Publikováno v: Journal of plastic, reconstructive & aesthetic surgery : JPRAS [J Plast Reconstr Aesthet Surg] 2024 Apr; Vol. 91, pp. 268-275. Date of Electronic Publication: 2024 Feb 07.